Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos.
Popular Articles

2009 Recipient Of Minority Scholar Award Begins Clinical Research On Leukemia
Alejandro Gutierrez, MD, is the third recipient of the ASH-AMFDP grant, an award designed to help increase the number of underrepresented minority scholars in the field of hematology, and will begin his research into the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL) this month. The award, the result of a partnership between the American Society of Hematology (ASH) and the Harold Amos Medical Faculty Development Program (AMFDP) of the Robert Wood Johnson Foundation, provides four years of support, including an annual stipend of up to $75,000 and an annual grant of more than $29,000 for research activities.
pharmacy online
Molecular Machinery Related To Stem Cell Fate Revealed By Xie Lab
The Stowers Institute"s Xie Lab has revealed how the BAM protein affects germline stem cell differentiation and how it is involved in regulating the quality of stem cells through intercellular competition. The work was published by PNAS Early Edition.
News of the day
Swine Flu Daily Update Issued At: 11am Wednesday 8 July 2009. Wales
-- The NPHS influenza surveillance scheme, which records reports of diagnoses of flu from more than 300 GP practices across Wales, shows low levels of influenza activity in all parts of Wales. Further detail can be found on the NPHS website.
Oncology

Positive Preclinical Data On 2 Product Candidates At ENDO 09 Presented By Versartis

Versartis, Inc., an emerging company developing novel biologics with enhanced properties for patients with metabolic diseases, presented data for its long-acting product candidates, VRS-317 (hGH-rPEG) for treatment of growth hormone deficiency and for VRS-826 (IL-1ra-rPEG) for treatment of type 1 and type 2 diabetes, at the Endocrine Society"s Annual Meeting in Washington, DC. Versartis, through a unique licensing agreement with Amunix, Inc., uses the Amunix proprietary recombinant PEGylation (rPEG) technology to extend the half-life of established biologics. The preclinical Versartis compounds have the potential for significantly less frequent dosing and fewer side effects than those products currently on the market or in development. "New half-life extension data presented for the first time confirmed our expectation that dosing can be extended from weekly to monthly for our product candidates," said Jeffrey L. Cleland, Ph.D., Founder and Chief Executive Officer of Versartis. "Our preclinical data show that VRS-317 demonstrated in vivo potency equal to daily hGH, and sustained plasma levels and pharmacodynamic responses in monkeys without toxicity. Potential benefits of VRS-317 include its stability at room temperature in a liquid formulation and the ability to dose monthly with a small gauge needle, thus increasing patient safety and convenience. VRS-317 may become "best in class" hGH therapy when our preclinical studies are confirmed in human clinical trials." "Treatment of auto-inflammation in diabetes with IL-1ra has been demonstrated to increase beta-cell responsiveness in human clinical trials," Dr. Cleland continued. "Our new approach with VRS-826 will provide a less frequently administered treatment that should have comparable safety to IL-1ra, which binds both IL-1b and IL-1a. The results from preclinical studies of VRS-317 and VRS-826 were presented in poster sessions." An Extended Half-Life Human Growth Hormone Construct for Weekly Administration hGH-rPEG Poster Board Number P1-720 Wednesday, June 10, 2009 1:30 - 3:30 pm A Long Half-Life Interleukin-1-Receptor Antagonist for the Treatment of Type 2 Diabetes Mellitus IL-1ra-rPEG Poster Board Number P1-466 Wednesday, June 10,2009 1:30 - 3:30 pm Debra Bannister Versartis, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009